Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
1.230
-0.060 (-4.65%)
At close: Mar 28, 2025, 4:00 PM
1.245
+0.015 (1.22%)
After-hours: Mar 28, 2025, 7:53 PM EDT
Biodexa Pharmaceuticals Revenue
Biodexa Pharmaceuticals had revenue of 83.00K GBP in the twelve months ending June 30, 2024, down -84.31% year-over-year. In the year 2023, Biodexa Pharmaceuticals had annual revenue of 381.00K, down -45.49%.
Revenue (ttm)
83.00K GBP
Revenue Growth
-84.31%
P/S Ratio
2.24
Revenue / Employee
3,952 GBP
Employees
21
Market Cap
822.37K USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 381.00K | -318.00K | -45.49% |
| Dec 31, 2022 | 699.00K | 121.00K | 20.93% |
| Dec 31, 2021 | 578.00K | 235.00K | 68.51% |
| Dec 31, 2020 | 343.00K | -331.00K | -49.11% |
| Dec 31, 2019 | 674.00K | -1.26M | -65.22% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
BDRX News
- 11 days ago - With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - Accesswire
- 20 days ago - Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP - GlobeNewsWire
- 24 days ago - Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP - GlobeNewsWire
- 4 weeks ago - Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use - GlobeNewsWire
- 6 weeks ago - Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 - GlobeNewsWire
- 6 weeks ago - Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Accesswire
- 6 weeks ago - Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis - GlobeNewsWire
- 2 months ago - Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer - GlobeNewsWire